Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2019

View Archived Issues

CD16-IL-15-CLEC12A TriKE demonstrates preclinical activity in models of AML

PTMs affect, as well as are affected by, protein folding

Gut-derived plasma cells suppress MS

Discontinuing tumor treatment can push cells into temporary retirement

BlackThorn Therapeutics offers pipeline update

BCAR3 as novel biomarker of prognosis in patients with multiple myeloma

Final safety results presented from phase I study of BT-11 in healthy volunteers

SH-498 presented as a promising anti-BMI-1 compound for colorectal cancer

Incyte begins phase I study of INCB-086550 in advanced solid tumors

Homology Medicines nominates in vivo gene editing development candidate for PKU

Epclusa approved in Japan for HCV

Forbius initiates phase I trial of AVID-200 in solid tumors

Etrasimod demonstrates long-term clinical remission in phase II OLE study for ulcerative colitis

Phase III study of SAGE-217 in postpartum depression meets primary and secondary endpoints

ProQR agrees with FDA on phase II/III trial design for QR-110 in Leber's congenital amaurosis 10

LINC00165 shown to promote progression of gastric cancer

FDA clears PrimeVax's IND for first-in-human trial in melanoma

FDA accepts IND for bispecific antibody MCLA-145

ContraFect reports topline phase II results for exebacase in S. aureus bacteremia

Promising phase II data presented for AK-002 in Xolair-naive chronic spontaneous urticaria patients

Minnebro approved in Japan for hypertension

Universite Laval patents IL-6 expression inhibitors

Quretech Bio AB and Washington University present new antibacterials

Novartis AG discloses new compounds for protozoal infections

Phase II ASCEND study of AXS-05 in major depressive disorder meets primary endpoint

Zhejiang Hisun Pharmaceutical describes ACC inhibitors

CIMA presents new compounds for cancer